UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549,,
FORM 12b-25,,
,,SEC FILE NUMBER
0-9065
,,
NOTIFICATION OF LATE FILING,,
,,,,CUSIP NUMBER
381145101
(Check One): Form 10-K Form 20-F Form 11-K Form 10-Q
Form N-SAR,,
For Period Ended: November 30, 1995
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended:
Read Instruction (on back page) Before Preparing Form. Please
Print or Type.
Nothing in this form shall be construed to imply that the
Commission has verified any
information contained herein.
If the notification relates to a portion of the filing checked
above, identify the Item(s) to
which the notification relates:
PART I REGISTRANT INFORMATION
Golden Pharmaceuticals, Inc.
Full Name of Registrant
Former Name if Applicable
1313 Washington Avenue
Address of Principal Executive Office (Street and Number)
Golden, Colorado 80401
City, State and Zip Code
PART II RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable
effort or expense and the
registrant seeks relief pursuant to Rule 12b-25(b), the following
should be completed.
(Check box if appropriate)
,(a) The reasons described in reasonable detail in Part III of
this form could not be
eliminated without unreasonable effort or expense;
,(b) The subject annual report, semi-annual report,
transition report on Form 10-K,
Form 20-F, 11-K or Form N-SAR, or portion thereof, will be
filed on or before
the fifteenth calendar day following the prescribed due
date; or the subject
quarterly report of transition report on Form 10-Q, or
portion thereof will be filed
on or before the fifth calendar day following the prescribed
due date; and
,(c) The accountant's statement or other exhibit required by
Rule 12b-25(c) has been
attached if applicable.
PART III NARRATIVE
State below in reasonable detail the reasons why Forms 10-K,
20-F, 11-K, 10-Q, N-SAR,
or the transition report or portion thereof, could not be filed
within the prescribed time
period.
Please See Attached.
PART IV OTHER INFORMATION
(1),Name and telephone number of person to contact in regard to
this notification,
, Glen H. Weaver
(Name), (303)
(Area Code), 279-9375
(Telephone Number)
,,
(2),Have all other periodic reports required under Section 13 or
15(d) of
the Securities Exchange Act of 1934 or Section 30 of the
Investment
Company Act of 1940 during the preceding 12 months or for such
shorter
period that the registrant was required to file such report(s)
been
filed? If answer is no, identify report(s).
,
Yes No
,,
(3),Is it anticipated that any significant change in results of
operations
from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the
subject
report or portion thereof?,
Yes No
,
,If so, attach an explanation of the anticipated change, both
narratively and
quantitatively, and, if appropriate, state the reasons why a
reasonable estimate
of the results cannot be made.
Golden Pharmaceuticals, Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the
undersigned hereunto
duly authorized.
Date January 17, 1996 By /s/ Glen
H. Weaver
Glen H. Weaver, Vice
President, Finance
INSTRUCTION: The form may be signed by an executive officer of
the registrant or
by any other duly authorized representative. The name and title
of the person signing
the form shall be typed or printed beneath the signature. If the
statement is signed on
behalf of the registrant by an authorized representative (other
than an executive officer),
evidence of the representative's authority to sign on behalf of
the registrant shall be filed
with the form.
, ATTENTION,
Intentional misstatements or omissions of fact constitute Federal
Criminal Violations (See
18 U.S.C. 1001).
GENERAL INSTRUCTIONS
1. This form is required by Rule 12b-25 (17 CFR 240.12b-25) of
the General Rules
and Regulations under the Securities Exchange Act of 1934.
2. One signed original and four conformed copies of this form
and amendments
thereto must be completed and filed with the Securities
and Exchange
Commission, Washington, D.C. 20549, in accordance with Rule
0-3 of the
General Rules and Regulations under the Act. The
information contained in or
filed with the form will be made a matter of public record
in the Commission files.
3. A manually signed copy of the form and amendments thereto
shall be filed with
each national securities exchange on which any class of
securities of the registrant
is registered.
4. Amendments to the notifications must also be filed on form
12b-25 but need not
restate information that has been correctly furnished. The
form shall be clearly
identified as an amended notification.
5. Electronic Filers. This form shall not be used by
electronic filers unable to timely
file a report solely due to electronic difficulties.
Filers unable to submit a report
within the time period prescribed due to difficulties in
electronic filing should comply
with either Rule 201 or Rule 202 of Regulation S-T
(232.201 or 232.202 of this
chapter) or apply for an adjustment in filing date pursuant
to Rule 13(b) of
Regulation S-T (232.13(b) of this chapter).
PART III - NARRATIVE
On August 7, 1995, the Registrant acquired all of the
outstanding capital stock of Quality Care Pharmaceuticals,
Inc., a
California corporation ("QCP") (the "Acquisition") for an
aggregate
purchase price of $3,718,750. The consolidation of the
operations
of QCP with Company's the three month period ended November
30,
1995 has resulted in extensivechanges to the financial
statements
of the Registrant. Therefore the Registrant is unable to
timely
complete the information required for the presentation of
its
Quarterly Report on Form 10-QSB for the period ending
November 30,
1995.
PART IV - OTHER INFORMATION
3. The consolidation of the operations of QCP with the
Company's
for the three months ended November 30, 1995 will have a
significant impact on the balance sheet and results of
operations
of the Registrant as compared to the corresponding period
for the
last fiscal year.
Anticipated condensed financial information for the
Registrant
is as follows:
11-30-95
11-30-94
Balance Sheets
Current Assets $ 2,540,263 $
888,182
Property, Plant and Equipment 1,078,060
528,782
Other Assets 4,335,799
65,757
$ 7,954,122 $
1,482,721
Current Liabilities $ 1,988,243 $
326,289
Other Liabilities 4,373,745
326,566
Equity 1,545,293
829,867
$ 7,907,281 $
1,482,721
Income Statements
Revenues $ 2,264,773 $
898,560 Costs and expenses 2,350,367
630,414
Net Income $ (85,594) $
268,146*
Net Income per common share $ * $
*
_____________
* After extraordinary item of $99,677.
January 17, 1995
United States Securities
and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
Attn: Filing Desk
Re: Golden Pharmaceuticals, Inc.
Ladies and Gentlemen:
Pursuant to Rule 12b-25 of the Securities Exchange Act of
1934, submitted herewith for filing is Golden Pharmaceuticals,
Inc.'s Form 12b-25 Notification of Late Filing of Form 10-QSB for
the quarter ended November 30, 1995.
This filing is being effected by direct transmission to the
Securities and Exchange Commission's Operational EDGAR System.
Please contact the undersigned at (303) 297-2400 if there
are
any questions.
Sincerely,
/s/ Deborah A. Hogan
Deborah A. Hogan
